INSIGHTS ON DRUG DEVELOPMENT

• Scientific Data Is Not AI‑Ready By Default

  Convert siloed laboratory data into trusted, AI-ready assets. Learn to enforce data integrity principles at the point of origin to streamline analytics and reduce GxP compliance risks.

• Amorphous Stability: Mesoporous Silica For Poor Glass Formers

  Discover how mesoporous silica outperforms polymeric solid dispersions in stabilizing poor glass formers, as well as how it offers a novel approach to enhance amorphous drug stability and bioavailability.

• Patient-Centric Formulations In Pediatric Adherence

  Improving pediatric adherence requires age-appropriate formulations, taste-masking, and swallowability strategies. Regulatory, clinical, and technological insights help overcome barriers and support safer, more effective therapies for children across developmental stages.

• CMC (Chemistry, Manufacturing and Controls) Management

  Eliminate regulatory risks caused by fragmented data. Learn how a continuous data thread from bench to batch streamlines tech transfer and accelerates filing timelines.

• Enhancing Throughput And Reproducibility In Proteomic Analysis

  8/27/2025

  Streamline proteomic workflows with consistent sample preparation. Discover how simplifying LC-MS processes can eliminate bottlenecks, improve reproducibility, and accelerate drug discovery research.

• The Role Of CDMOs In Supporting Generic Drug Development

  7/15/2025

  Bringing complex generics to market requires deep expertise. Learn how a CDMO can help navigate regulatory, technical, and commercial challenges with end-to-end development and manufacturing support.

• Comprehensive GMP Testing Services

  3/31/2025

  Eurofins delivers global GMP testing with 45+ facilities, ensuring regulatory acceptance, quality, and trusted service from starting materials to finished products.

• UPLC-MS/MS Determination Of GLP-1 Analogue

  7/17/2025

  Discover a robust, evaporation-free method for analyzing liraglutide in human plasma using LC-MS/MS to ensure high sensitivity, reproducibility, and improved analyte recovery.

• A Comparison To Traditional Clone Screening Platforms

  8/6/2026

  See how 46 CHO clones performed across automated, deep-well, and microbioreactor fed-batch cultures, using cell density, viability, and IgG concentration to evaluate clone performance.